Ozempic Becomes Affordable in India
The cost of Ozempic in India has dropped significantly, removing a major barrier to access for the country's vast population with diabetes. This development is expected to drive widespread adoption of advanced GLP-1 therapies, potentially impacting CPG strategies in the health and wellness sectors across emerging markets.
Manufacturer Novo Nordisk set Ozempic's initial monthly price in India between ₹8,800 and ₹11,175 ($112-$142), depending on the dosage. This pricing is substantially lower than in the United States, where monthly costs can range from $900 to $1,300 without significant insurance coverage. The move targets a massive market, as India has 90 million adults with diabetes, second only to China. An additional 136 million people in the country are considered pre-diabetic, highlighting the significant potential for growth in metabolic health treatments. Novo Nordisk's pricing strategy is a preemptive strike against looming competition. The patent for semaglutide, Ozempic's active ingredient, is set to expire in India in March 2026. This strategic timing allows the company to establish a strong market presence and brand recognition before lower-cost alternatives become available. Following the patent expiry, major Indian pharmaceutical companies, including Dr. Reddy's Laboratories, Sun Pharma, and Zydus Lifesciences, are expected to launch generic versions of the drug. Analysts project these generics could be priced at a 50% discount or more, potentially dropping the monthly cost to between ₹3,500 and ₹5,000. To defend its market share, Novo Nordisk is expanding its distribution network and product offerings. The company has partnered with Abbott to market a second brand of semaglutide called Extensior and has a distribution agreement with Emcure Pharma to broaden access beyond major metropolitan areas. Despite the price reduction, affordability remains a key factor in widespread adoption. The list price for a month's supply of Wegovy, a similar drug, represents about 60% of India's median monthly income. The introduction of generics is seen as the critical driver for making GLP-1 therapies accessible to India's broader middle class. The increased availability of these therapies could have significant downstream effects on consumer-packaged goods. As GLP-1 drugs are known to impact appetite and food choices, their adoption may alter consumption patterns, particularly in India, which is the world's largest consumer of sugar.
